Supplementary Material
## Supplementary Tables

### Table s1. Comorbidities, results from risk stratification and outcomes of study patients stratified according to the availability of hsTnI measurements

| Comorbidities                                      | All patients (n=742) | Patients with hsTnI measurements (n=459) | Patients without hsTnI measurements (n=283) | p-value |
|---------------------------------------------------|----------------------|-----------------------------------------|---------------------------------------------|---------|
| Age ≥75 years                                      | 249 (33.6%)          | 155 (33.8%)                             | 94 (33.2%)                                  | 0.88    |
| Sex (female)                                       | 388 (52.3%)          | 241 (52.5%)                             | 147 (51.9%)                                 | 0.88    |
| **Comorbidities**                                 |                      |                                         |                                             |         |
| Chronic heart failure                             | 105 (14.2%)          | 59 (12.9%)                              | 46 (16.3%)                                  | 0.20    |
| Coronary artery disease                           | 121 (16.3%)          | 67 (14.6%)                              | 54 (19.1%)                                  | 0.11    |
| Chronic pulmonary disease                         | 110 (14.8%), n=741   | 60 (13.1%), n=458                       | 50 (17.7%)                                  | 0.09    |
| Diabetes mellitus                                 | 115 (15.5%)          | 65 (14.2%)                              | 50 (17.7%)                                  | 0.20    |
| Renal insufficiency                               | 222 (30.5%), n=729   | 134 (29.2%)                             | 88 (32.6%), n=270                           | 0.34    |
| Active cancer                                      | 155 (20.9%)          | 110 (24.0%)                             | 45 (15.9%)                                  | 0.009   |
| **Symptoms at presentation**                      |                      |                                         |                                             |         |
| Dyspnoea                                           | 589 (79.7%), n=739   | 359 (78.6%), n=457                      | 230 (81.6%), n=282                          | 0.32    |
| Syncope                                            | 90 (12.2%), n=740    | 53 (11.6%), n=457                       | 37 (13.1%)                                  | 0.55    |
| Altered mental status                             | 34 (4.6%), n=741     | 19 (4.1%), n=458                        | 15 (5.3%)                                   | 0.47    |
| **Clinical findings at presentation**             |                      |                                         |                                             |         |
| Tachycardia                                        | 236 (32.8%), n=719   | 135 (30.4%), n=444                      | 101 (36.7%), n=275                          | 0.08    |
| Hypoxemia                                          | 134 (19.8%), n=612   | 74 (19.8%), n=374                       | 60 (25.2%), n=238                           | 0.11    |
| **Laboratory and imaging markers**                |                      |                                         |                                             |         |
| hsTnT ≥14 pg/ml                                    | 433 (63.2%), n=685   | 271 (61.0%), n=444                      | 162 (67.2%), n=241                          | 0.11    |
| NT-proBNP ≥600 pg/ml                              | 326 (49.9%), n=653   | 212 (47.5%), n=446                      | 114 (55.1%), n=207                          | 0.07    |
| RV/LV diameter ratio ≥1.0 on CTPA                 | 443 (67.4%), n=657   | 270 (65.4%), n=413                      | 173 (70.9%), n=244                          | 0.14    |
| **Risk stratification**                           |                      |                                         |                                             |         |
| modified FAST score ≥3 points^a                    | 182 (24.5%)          | 100 (21.8%)                             | 82 (29.0%)                                  | 0.027   |
| ESC 2019 algorithm^a                               | 90 (12.1%)           | 56 (12.2%)                              | 34 (12.0%)                                  | 0.24    |
| Low risk                                           | 396 (53.4%)          | 255 (55.6%)                             | 141 (49.8%)                                 |         |
| Intermediate-low risk                              | 256 (34.5%)          | 148 (32.3%)                             | 108 (38.2%)                                 |         |
| Intermediate-high risk                             |                      |                                         |                                             |         |
| **Outcome**                                        |                      |                                         |                                             |         |
| In-hospital adverse outcome                        | 42 (5.7%)            | 22 (4.8%)                               | 20 (7.1%)                                   | 0.19    |
| Catecholamine administration                      | 31 (4.2%)            | 15 (3.3%)                               | 16 (5.7%)                                   | 0.11    |
| Cardiopulmonary resuscitation                     | 14 (1.9%)            | 5 (1.1%)                                | 9 (3.2%)                                    | 0.042   |
| PE-related death                                   | 16 (2.2%)            | 9 (2.0%)                                | 7 (2.5%)                                    | 0.64    |
| In-hospital all-cause mortality                    | 29 (3.9%)            | 14 (3.1%)                               | 15 (5.3%)                                   | 0.12    |

^a calculation of scores based on hsTnI measurements

**Abbreviations:** HsTnI denotes high-sensitivity troponin I; hsTnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide; RV/LV, right/left ventricle; CTPA, computed tomography pulmonary angiography; ESC, European Society of Cardiology; PE, pulmonary embolism.
Supplementary Figures

Figure s1: Rate of an in-hospital adverse outcome stratified according to hsTnI levels at presentation

| hsTnI concentration at presentation | Rate of in-hospital adverse outcome | n  |
|-------------------------------------|-------------------------------------|----|
| ≤10 pg/ml                           | 2%                                  | 177|
| 10.1-27 pg/ml                      | 5%                                  | 91 |
| 27.1-100 pg/ml                     | 6%                                  | 83 |
| >100 pg/ml                         | 9%                                  | 108|

p<0.002 for trend